{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T17:06:06Z","timestamp":1769879166931,"version":"3.49.0"},"reference-count":38,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,7,8]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to estimate the cost\u2013utility of sofosbuvir\/velpatasvir (SOF\/VEL) compared with other direct-acting antivirals (DAAs) in Chinese patients with hepatitis C virus (HCV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A Markov model was developed to estimate the disease progression of patients with HCV over a lifetime horizon from the healthcare system perspective. Efficacy, clinical inputs and utilities were derived from the published literature. Drug costs were from the market price survey, and health costs for Markov health states were sourced from a Chinese study. Costs and utilities were discounted at an annual rate of 5%. One-way and probabilistic sensitivity analyses were conducted to test the impact of input parameters on the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>SOF\/VEL was compared with sofosbuvir+ribavirin (SR), sofosbuvir+dasabuvir (SD), daclatasvir+asunaprevir (DCV\/ASV), ombitasvir\/paritaprevir\/ritonavir+dasabuvir (3D) and elbasvir\/grazoprevir (EBR\/GZR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcomes<\/jats:title>\n                    <jats:p>Costs, quality-adjusted life years (QALYs) and incremental cost\u2013utility ratios (ICURs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SOF\/VEL was economically dominant over SR and SD. However, 3D was economically dominant compared with SOF\/VEL. Compared with DCV\/ASV, SOF\/VEL was cost-effective with the ICUR of US$1522 per QALY. Compared with EBR\/GZR, it was not cost-effective with the ICUR of US$369 627 per QALY. One-way sensitivity analysis demonstrated that reducing the cost of SOF\/VEL to the lower value of CI resulted in dominance over EBR\/GZR and 3D. Probabilistic sensitivity analysis demonstrated that 3D was cost-effective in 100% of iterations in patients with genotype (GT) 1b and SOF\/VEL was not cost-effective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with other oral DAA agents, SOF\/VEL treatment was not the most cost-effectiveness option for patients with chronic HCV GT1b in China. Lower the price of SOF\/VEL will make it cost-effective while simplifying treatment and achieving the goal of HCV elimination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-035224","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T06:38:52Z","timestamp":1597991932000},"page":"e035224","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Cost\u2013utility of sofosbuvir\/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6338-9418","authenticated-orcid":false,"given":"Haoya","family":"Yun","sequence":"first","affiliation":[{"name":"Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China"},{"name":"NHC Key Laboratory of Health Economics and Policy Research, Shandong University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China"},{"name":"NHC Key Laboratory of Health Economics and Policy Research, Shandong University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojie","family":"Sun","sequence":"additional","affiliation":[{"name":"Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China"},{"name":"NHC Key Laboratory of Health Economics and Policy Research, Shandong University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizheng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"2025121422462058000_10.8.e035224.1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121422462058000_10.8.e035224.2","unstructured":"World Health Organization . Hepatitis C. fact sheet. Available: http:\/\/ www.who.int\/mediacentre\/factsheets\/fs164\/en\/ [Accessed 27 Jul 2019]."},{"key":"2025121422462058000_10.8.e035224.3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/jgh.12220","article-title":"Update on epidemiology of hepatitis B and C in China","volume":"28 Suppl 1","author":"Cui","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"2025121422462058000_10.8.e035224.4","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12398"},{"key":"2025121422462058000_10.8.e035224.5","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12625"},{"key":"2025121422462058000_10.8.e035224.6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26218"},{"key":"2025121422462058000_10.8.e035224.7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ396"},{"key":"2025121422462058000_10.8.e035224.8","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-0748-8"},{"key":"2025121422462058000_10.8.e035224.9","first-page":"192","article-title":"The guidelines of prevention and treatment for chronic hepatitis C (2015 updated version)","volume":"33","year":"2015","journal-title":"Chinese Hepatology"},{"key":"2025121422462058000_10.8.e035224.10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/liv.13027","article-title":"Direct-Acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives","volume":"36 Suppl 1","author":"Asselah","year":"2016","journal-title":"Liver Int"},{"key":"2025121422462058000_10.8.e035224.11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/liv.12745","article-title":"Optimal IFN-free therapy in treatment-na\u00efve patients with HCV genotype 1 infection","volume":"35 Suppl 1","author":"Asselah","year":"2015","journal-title":"Liver Int"},{"key":"2025121422462058000_10.8.e035224.12","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s40265-016-0648-2","article-title":"Sofosbuvir\/Velpatasvir: a review in chronic hepatitis C","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"2025121422462058000_10.8.e035224.13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240201"},{"key":"2025121422462058000_10.8.e035224.14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijid.2014.07.003","article-title":"Fibrosis progression in interferon treatment-naive Chinese plasma donors with chronic hepatitis C for 20 years: a cohort study","volume":"27","author":"Li","year":"2014","journal-title":"Int J Infect Dis"},{"key":"2025121422462058000_10.8.e035224.15","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1336"},{"key":"2025121422462058000_10.8.e035224.16","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1152"},{"key":"2025121422462058000_10.8.e035224.17","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jval.2017.05.003","article-title":"Cost-Utility of Elbasvir\/Grazoprevir in patients with chronic hepatitis C genotype 1 infection","volume":"20","author":"Corman","year":"2017","journal-title":"Value Health"},{"key":"2025121422462058000_10.8.e035224.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"2025121422462058000_10.8.e035224.19","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0785"},{"key":"2025121422462058000_10.8.e035224.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"2025121422462058000_10.8.e035224.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.08.015"},{"key":"2025121422462058000_10.8.e035224.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61059-X"},{"key":"2025121422462058000_10.8.e035224.23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003004","article-title":"Systematic review and network meta-analysis of randomized controlled trials","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine"},{"key":"2025121422462058000_10.8.e035224.24","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jgh.14102","article-title":"Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: results from a phase 3B study in China","volume":"33","author":"Wei","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"2025121422462058000_10.8.e035224.25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22375"},{"key":"2025121422462058000_10.8.e035224.26","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9024300"},{"key":"2025121422462058000_10.8.e035224.27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24370"},{"key":"2025121422462058000_10.8.e035224.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.01.005"},{"key":"2025121422462058000_10.8.e035224.29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40261-018-0621-9","article-title":"Cost effectiveness of daclatasvir plus asunaprevir therapy for Chinese patients with chronic hepatitis C virus genotype 1B","volume":"38","author":"Liu","year":"2018","journal-title":"Clin Drug Investig"},{"key":"2025121422462058000_10.8.e035224.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03021.x"},{"key":"2025121422462058000_10.8.e035224.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155934","article-title":"Will sofosbuvir\/ledipasvir (Harvoni) be cost-effective and affordable for Chinese patients infected with hepatitis C virus? an economic analysis using real-world data","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One"},{"key":"2025121422462058000_10.8.e035224.32","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/03007995.2018.1546678","article-title":"Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis C","volume":"35","author":"Wu","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2025121422462058000_10.8.e035224.33","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X08315240"},{"key":"2025121422462058000_10.8.e035224.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40976.x"},{"key":"2025121422462058000_10.8.e035224.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175189","article-title":"Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS One"},{"key":"2025121422462058000_10.8.e035224.36","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40261-018-0702-9","article-title":"Cost-Effectiveness of Elbasvir\/Grazoprevir versus daclatasvir plus asunaprevir in patients with chronic hepatitis C virus genotype 1B infection in China","volume":"38","author":"Chen","year":"2018","journal-title":"Clin Drug Investig"},{"key":"2025121422462058000_10.8.e035224.37","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/jgh.14301","article-title":"Cost-effectiveness of generic pan-genotypic sofosbuvir\/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment","volume":"33","author":"Goel","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"2025121422462058000_10.8.e035224.38","unstructured":"Organization WH . Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. WHO, 2018."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-035224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:46:34Z","timestamp":1765781194000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-035224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,20]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bmjopen-2019-035224"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-035224","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}